SCHEMBL6035017

SCHEMBL6035017

CCOc1nn(Cc2ccccc2)cc1CCCO

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
HDAC1 Q13547 2/20 0.41
HDAC7 Q8WUI4 2/20 0.41
PDE4D Q08499 1/20 0.41
CREBBP Q92793 1/20 0.40
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
ALDH1A1 P00352 2/20 0.39
LMNA P02545 1/20 0.39
CYP19A1 P11511 4/20 0.38
CACNA1G O43497 1/20 0.38
CACNA1H O95180 1/20 0.38
CACNA1I Q9P0X4 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
DGAT1 O75907 1/20 0.37
LTA4H P09960 1/20 0.37
EPHX2 P34913 1/20 0.37
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6034607 0.96 HDAC1 (0.43) POLBHDAC1HDAC7PDE4DCREBBP
SCHEMBL6035864 0.85 SMN1; SMN2 (0.41) HDAC1HDAC7CREBBPALDH1A1LMNA
SCHEMBL6034538 0.84 HDAC1 (0.38) HDAC1HDAC7CREBBPALDH1A1LMNA
SCHEMBL6035970 0.83 HDAC1 (0.37) POLBHDAC1HDAC7CREBBPALDH1A1
SCHEMBL5373814 0.81 CYP4F2 (0.50) HDAC1HDAC7CREBBPALDH1A1LMNA
SCHEMBL6035946 0.80 HDAC1 (0.39) HDAC1HDAC7CREBBPALDH1A1LMNA
SCHEMBL6034540 0.78 CREBBP (0.38) HDAC1HDAC7PDE4DCREBBPALDH1A1
SCHEMBL5380360 0.78 ALDH1A1 (0.49) POLBCREBBPALDH1A1LMNACACNA1G
SCHEMBL6035127 0.77 POLB (0.44) POLBHDAC1HDAC7PDE4DCYP11B1
SCHEMBL5393507 0.77 CNR1 (0.50) ALDH1A1LMNACYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 POLB 4532/4885HDAC1 398/4885HDAC7 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.